These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39001472)

  • 21. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
    Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
    J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation Between Circulating Tumor Cell DNA Genomic Alterations and Mesenchymal CTCs or CTC-Associated White Blood Cell Clusters in Hepatocellular Carcinoma.
    Wang C; Luo Q; Huang W; Zhang C; Liao H; Chen K; Pan M
    Front Oncol; 2021; 11():686365. PubMed ID: 34178679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
    Matsumae T; Kodama T; Myojin Y; Maesaka K; Sakamori R; Takuwa A; Oku K; Motooka D; Sawai Y; Oshita M; Nakabori T; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
    Kaneko Y; Kaneshiro M; Watanabe H
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
    Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
    Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
    Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
    Tamura Y; Ono A; Nakahara H; Hayes CN; Fujii Y; Zhang P; Yamauchi M; Uchikawa S; Teraoka Y; Uchida T; Fujino H; Nakahara T; Murakami E; Tsuge M; Serikawa M; Miki D; Kawaoka T; Okamoto W; Imamura M; Nakamura Y; Awai K; Kobayashi T; Ohdan H; Fujita M; Nakagawa H; Chayama K; Aikata H; Oka S
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype.
    Yu JJ; Shu C; Yang HY; Huang Z; Li YN; Tao R; Chen YY; Chen Q; Chen XP; Xiao W
    Front Oncol; 2021; 11():734564. PubMed ID: 34722281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
    Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Yamauchi Y; Saeki I; Yamasaki T; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Nishimura T; Tanabe N; Oono T; Matsumoto T; Ishikawa T; Marumoto Y; Matsukuma S; Shindo Y; Tokumitsu Y; Yoshimine S; Murakami J; Tanaka T; Kimura S; Hoshii Y; Hamano K; Nagano H; Takami T
    Hepatol Res; 2023 Jul; 53(7):681-686. PubMed ID: 36826420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Kosaka M; Shirane Y; Johira Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Kosaka Y; Uchikawa S; Kodama K; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Okamoto W; Takahashi S; Imamura M; Aikata H
    Liver Cancer; 2023 Aug; 12(3):251-261. PubMed ID: 37601981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
    Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
    Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.
    Chuma M; Uojima H; Toyoda H; Hiraoka A; Arase Y; Atsukawa M; Itokawa N; Okubo T; Tada T; Numata K; Morimoto M; Sugimori M; Nozaki A; Iwasaki S; Yasuda S; Koshiyama Y; Mishima Y; Tsuruya K; Tokoro C; Miura Y; Hidaka H; Kumada T; Kusano C; Kagawa T; Maeda S
    Hepatol Int; 2024 Oct; 18(5):1472-1485. PubMed ID: 38963640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review.
    Sato S; Aoki T; Matsumoto T; Shiraki T; Mori S; Iso Y; Nemoto T; Onishi T; Iijima M; Ishida K
    Clin J Gastroenterol; 2024 Apr; 17(2):292-299. PubMed ID: 38071671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.